Top Markets
#1 Black Phoenix Black Phoenix +861.87%
#2 QuantixAI QuantixAI +102.94%
#3 MetaDAO MetaDAO +25.00%
#4 Bedrock Bedrock +21.77%
#5 Ontology Gas Ontology Gas +21.61%
#6 Pons Pons +20.95%
#7 龙虾 (Lobster) 龙虾 (Lobster) +20.42%
#8 Siren Siren +20.12%
#9 SPX6900 SPX6900 +18.34%
#10 DOG•GO•TO•THE•MOON (Runes) DOG•GO•TO•THE•MOON (Runes) +16.35%
Coin of the day
Black Phoenix Black Phoenix
Instellingen
Taal
DUTCH
Valuta
USD
Thema
Grifols, S.A. Grifols, S.A.

Grifols, S.A.

GRF
Rang in aandelen #2537
Grifols, S.A., a Spanish company established in 1940 and headquartered in... Grifols, S.A., a Spanish company established in 1940 and headquartered in Barcelona, specializes in the comprehensive process of acquiring, manufacturing, preparing, and distributing therapeutic products, with a primary focus on those derived from plasma. The company operates through several key divisions: Bioscience, Hospital, Diagnostic, and Bio Supplies, among others. The Bioscience division is dedicated to the research, development, production, and commercialization of plasma-derived medicines and other cutting-edge solutions. These are designed to treat individuals suffering from chronic, rare, widespread, and life-threatening medical conditions, with its product portfolio including immunoglobulins, alpha-1 antitrypsin, albumin, clotting factors, and hyperimmune globulins. The Hospital division supplies a range of non-biological pharmaceutical products, clinical nutrition items, intravenous (IV) therapy solutions, and various medical devices and supplies. Grifols' Diagnostic division develops and markets advanced diagnostic tools that support healthcare professionals across the entire patient care continuum, from prevention and screening to accurate diagnosis, prognosis, and ongoing disease and treatment monitoring. Finally, the Bio Supplies division provides essential biological materials for life-science research, clinical trials, and the manufacturing of both pharmaceutical and diagnostic goods. Collectively, Grifols' offerings enable healthcare providers to effectively diagnose and treat a broad spectrum of medical conditions, such as hemophilia, various immune deficiencies, and infectious diseases. Its diverse client base includes public and private sector organizations, wholesalers, distributors, group purchasing organizations (GPOs), blood banks, hospitals, care institutions, and national health systems. Grifols also maintains a technology collaboration agreement with Mondragon.
Aandeelprijs
$11.91
Marktkapitalisatie
$8.11B
Verandering (1 dag)
1.67%
Verandering (1 jaar)
-16.23%
Land
ES
Handel Grifols, S.A. (GRF)

Categorie

Healthcare
Winst voor Grifols, S.A. (GRF)
Winst in 2026 TTM: 0
Volgens de meest recente financiële verslagen van Grifols, S.A. bedraagt de huidige winst van het bedrijf 0. In 2026 behaalde het bedrijf een winst van 0, gelijk aan de winst van 2026, die 0 bedroeg. De weergegeven winst op deze pagina is de winst vóór rente en belastingen, oftewel EBIT.
Winstgeschiedenis van Grifols, S.A. van 2026 tot 2026
Winst aan het einde van elk jaar
Jaar Winst Wijzigen
Niet genoeg gegevens voor de verstrekte datums.
Winst van vergelijkbare bedrijven of concurrenten
Bedrijf Winst Winstverschil Land
Eli Lilly and Company Eli Lilly and Company
Eli Lilly and Company
LLY.US
$33.59B -
US
Johnson & Johnson Johnson & Johnson
Johnson & Johnson
JNJ.US
$25.20B -
US
AbbVie Inc. AbbVie Inc.
AbbVie Inc.
ABBV.US
$8.70B -
US
Roche Holding AG Roche Holding AG
Roche Holding AG
RO.SW
$21.39B -
CH
Merck & Co., Inc. Merck & Co., Inc.
Merck & Co., Inc.
MRK.US
$5.95B -
US